Matches in SemOpenAlex for { <https://semopenalex.org/work/W1505262368> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W1505262368 abstract "Abstract Novel treatments are needed for older patients with AML who are not thought likely to benefit from standard chemotherapy. A recent randomised trial demonstrated that Low Dose Ara-C (LD Ara-C) was superior to best supportive care (BSC) (Burnett et al Cancer2007: 109: 1114–1124). The Farnesyl Transferase inhibitor, Tipifarnib, has produced encouraging responses in this patient group (Lancet 109; 1387–1394) although in a subsequent randomised comparison vs BSC it was not superior (Haroussea et al Blood1997:110,135a) The UK NCRI AML16 trial aims to test novel agents or combinations in untreated older patients with AML or high risk MDS (marrow blasts >10%) following a “pick a winner” design. The intention is to randomise up to 50 patients per arm with the expectation that a “winner” will achieve a remission rate in excess of 30%, compared with 15–20% with LD Ara-C. If that is achieved randomisation will continue with OS and DFS as endpoints. We report our experience of LD Ara-C (20mg bd days 1–10 for 4 courses versus LD Ara-C combined with Tipifarnib (300mg bd days 1–21) for 4 courses at 6–8 week intervals. Patient Details: Sixty-five patients were randomised between December 2006 and October 2007. The median age was 74.4 years with 82% of patients over 70 years. There were no differences between the treatment arms with respect to age distribution, gender, performance status, de novo/secondary AML, high risk MDS presenting WBC or cytogenetic risk group. Because of concerns about excess deaths in the Tipifarnib arm and therefore the low probability that LD Ara-C + Tipifarnib would be superior to LD Ara-C alone, the DMEC recommended premature closure of the Tipifarnib arm. Conclusions: While other agents combined with Tipifarnib may continue to show promise, the combination with LD-Ara-C in this patient population was not beneficial." @default.
- W1505262368 created "2016-06-24" @default.
- W1505262368 creator A5010009280 @default.
- W1505262368 creator A5013645809 @default.
- W1505262368 creator A5018693666 @default.
- W1505262368 creator A5031825598 @default.
- W1505262368 creator A5035489508 @default.
- W1505262368 creator A5046387225 @default.
- W1505262368 creator A5047494868 @default.
- W1505262368 date "2008-11-16" @default.
- W1505262368 modified "2023-09-30" @default.
- W1505262368 title "Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison" @default.
- W1505262368 doi "https://doi.org/10.1182/blood.v112.11.2962.2962" @default.
- W1505262368 hasPublicationYear "2008" @default.
- W1505262368 type Work @default.
- W1505262368 sameAs 1505262368 @default.
- W1505262368 citedByCount "3" @default.
- W1505262368 crossrefType "journal-article" @default.
- W1505262368 hasAuthorship W1505262368A5010009280 @default.
- W1505262368 hasAuthorship W1505262368A5013645809 @default.
- W1505262368 hasAuthorship W1505262368A5018693666 @default.
- W1505262368 hasAuthorship W1505262368A5031825598 @default.
- W1505262368 hasAuthorship W1505262368A5035489508 @default.
- W1505262368 hasAuthorship W1505262368A5046387225 @default.
- W1505262368 hasAuthorship W1505262368A5047494868 @default.
- W1505262368 hasConcept C121608353 @default.
- W1505262368 hasConcept C126322002 @default.
- W1505262368 hasConcept C143998085 @default.
- W1505262368 hasConcept C2992972558 @default.
- W1505262368 hasConcept C71924100 @default.
- W1505262368 hasConceptScore W1505262368C121608353 @default.
- W1505262368 hasConceptScore W1505262368C126322002 @default.
- W1505262368 hasConceptScore W1505262368C143998085 @default.
- W1505262368 hasConceptScore W1505262368C2992972558 @default.
- W1505262368 hasConceptScore W1505262368C71924100 @default.
- W1505262368 hasLocation W15052623681 @default.
- W1505262368 hasOpenAccess W1505262368 @default.
- W1505262368 hasPrimaryLocation W15052623681 @default.
- W1505262368 hasRelatedWork W1489910849 @default.
- W1505262368 hasRelatedWork W1501928312 @default.
- W1505262368 hasRelatedWork W1731671344 @default.
- W1505262368 hasRelatedWork W1940598690 @default.
- W1505262368 hasRelatedWork W1994169292 @default.
- W1505262368 hasRelatedWork W2025086811 @default.
- W1505262368 hasRelatedWork W2046180917 @default.
- W1505262368 hasRelatedWork W2080060037 @default.
- W1505262368 hasRelatedWork W2524621184 @default.
- W1505262368 hasRelatedWork W2563641652 @default.
- W1505262368 hasRelatedWork W2568035963 @default.
- W1505262368 hasRelatedWork W2580120603 @default.
- W1505262368 hasRelatedWork W2588102314 @default.
- W1505262368 hasRelatedWork W2594352053 @default.
- W1505262368 hasRelatedWork W2609558812 @default.
- W1505262368 hasRelatedWork W2922272916 @default.
- W1505262368 hasRelatedWork W2942117736 @default.
- W1505262368 hasRelatedWork W2980305339 @default.
- W1505262368 hasRelatedWork W3178765071 @default.
- W1505262368 hasRelatedWork W2561131947 @default.
- W1505262368 isParatext "false" @default.
- W1505262368 isRetracted "false" @default.
- W1505262368 magId "1505262368" @default.
- W1505262368 workType "article" @default.